Ilaria Spagnoletti

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis et al. · The Lancet Oncology · 2018 · 88 citations · Full text

Medicine, Endocrinology, Oncology +11

Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study

Marina Elena Cazzaniga, G. Pinotti, Emilia Montagna et al. · The Breast · 2019 · 57 citations

Medicine, Oncology, Breast Oncology +9

Randomised Phase II Trial (NCT00637975) Evaluating Activity and Toxicity of Two Different Escalating Strategies for Pregabalin and Oxycodone Combination Therapy for Neuropathic Pain in Cancer Patients

Marina Chiara Garassino, Sheila Piva, Nicla La Verde et al. · PLoS ONE · 2013 · 31 citations · Full text

Nursing, Pharmacology, Pharmacotherapy +17

Two mutations of BRCA2 gene at exon and splicing site in a woman who underwent oncogenetic counseling

Matilde Pensabene, Ilaria Spagnoletti, I. Capuano et al. · Annals of Oncology · 2009 · 24 citations · Full text

Life Sciences, Genetics, Molecular Genetics +10

Loss of hMSH2 expression in primary breast cancer with p53 alterations

Ilaria Spagnoletti, C. Pizzi, Annamaria Galietta et al. · Oncology Reports · 2004 · 20 citations

Medicine, Molecular Genetics, Oncology +12